Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy

Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).

(2017) D. Belada et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.

(2017) S. P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer

(2014) Simone Braig et al.   BIOCHEMICAL PHARMACOLOGY

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

(2014) SABRINA LABSCH et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis

(2014) Yen-Chuan Ou et al.   LIFE SCIENCES

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†

(2013) A. L. Cohn et al.   ANNALS OF ONCOLOGY

An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins

(2013) Aruljothi Subramaniam et al.   APOPTOSIS

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

(2013) Charles S. Fuchs et al.   CANCER

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

(2013) Zev A. Wainberg et al.   Clinical Colorectal Cancer

CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells

(2013) EUN YOUNG KIM et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation

(2013) KRIENGSAK LIRDPRAPAMONGKOL et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

Azadirone, a Limonoid Tetranortriterpene, Induces Death Receptors and Sensitizes Human Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) through a p53 Protein-independent Mechanism

(2013) Subash C. Gupta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

(2013) Martin Reck et al.   LUNG CANCER

Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway

(2013) HYE HYEON LEE et al.   ONCOLOGY REPORTS

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

(2013) Andres Forero-Torres et al.   Cancer Medicine

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins

(2012) Mi Hee Park et al.   APOPTOSIS

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

(2012) Caio M. Rocha Lima et al.   CANCER INVESTIGATION

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

(2012) George D. Demetri et al.   EUROPEAN JOURNAL OF CANCER

Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells

(2012) Ok-Won Seo et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS–JNK–CHOP-mediated upregulation of death receptors

(2012) Bokyung Sung et al.   FREE RADICAL BIOLOGY AND MEDICINE

Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells

(2012) K. Azijli et al.   JOURNAL OF CELL SCIENCE

Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

(2012) Melinda S. Merchant et al.   JOURNAL OF CLINICAL ONCOLOGY

Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation

(2012) Hu Xiaowen et al.   MOLECULAR BIOLOGY REPORTS

Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5

(2012) Eun Young Kim et al.   MOLECULES AND CELLS

Mitochondria: master regulators of danger signalling

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway

(2011) Yinhui Dong et al.   APOPTOSIS

Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo

(2011) Chong Zhang et al.   CANCER LETTERS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells

(2011) C Jennewein et al.   ONCOGENE

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

(2010) Andres Forero-Torres et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

(2010) T. Doi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells

(2010) C. Lepage et al.   CANCER LETTERS

TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1

(2010) J K Son et al.   CELL DEATH AND DIFFERENTIATION

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways

(2010) Feng-Lang Lin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

6-Dehydrogingerdione Sensitizes Human Hepatoblastoma Hep G2 Cells to TRAIL-Induced Apoptosis via Reactive Oxygen Species-Mediated Increase of DR5

(2010) Chung-Yi Chen et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Tricetin, a Dietary Flavonoid, Induces Apoptosis through the Reactive Oxygen Species/c-Jun NH2-Terminal Kinase Pathway in Human Liver Cancer Cells

(2010) Ya-Ling Hsu et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Nimbolide Sensitizes Human Colon Cancer Cells to TRAIL through Reactive Oxygen Species- and ERK-dependent Up-regulation of Death Receptors, p53, and Bax

(2010) Subash C. Gupta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors

(2010) Sahdeo Prasad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gossypol Induces Death Receptor-5 through Activation of the ROS-ERK-CHOP Pathway and Sensitizes Colon Cancer Cells to TRAIL

(2010) Bokyung Sung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation

(2010) Daniela Carlisi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Butein Sensitizes Human Hepatoma Cells to TRAIL-Induced Apoptosis via Extracellular Signal-Regulated Kinase/Sp1-Dependent DR5 Upregulation and NF- B Inactivation

(2010) D.-O. Moon et al.   MOLECULAR CANCER THERAPEUTICS

γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors

(2010) Ramaswamy Kannappan et al.   MOLECULAR CANCER THERAPEUTICS

New insights into apoptosis signaling by Apo2L/TRAIL

(2010) F Gonzalvez et al.   ONCOGENE

Activation of the Akt Survival Pathway Contributes to TRAIL Resistance in Cancer Cells

(2010) Jing Xu et al.   PLoS One

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5

(2009) Marine E. Gasparian et al.   APOPTOSIS

Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death

(2009) Kyung-Jin Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

Zerumbone Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors in Human Colon Cancer Cells: Evidence for an Essential Role of Reactive Oxygen Species

(2009) S. Yodkeeree et al.   CANCER RESEARCH

c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment

(2009) Jae J. Song et al.   CELLULAR SIGNALLING

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Src and ADAM-17-Mediated Shedding of Transforming Growth Factor-  Is a Mechanism of Acute Resistance to TRAIL

(2008) S. Van Schaeybroeck et al.   CANCER RESEARCH

TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2

(2008) U. Vilimanovich et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily

(2008) Jae J. Song et al.   CELLULAR SIGNALLING

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand

(2008) S R Mucha et al.   GUT

Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting IκBα Kinase-NFκB

(2008) Chen Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

(2008) Anne Grosse-Wilde et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8

(2008) Larisa L. Belyanskaya et al.   LUNG CANCER

Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation

(2008) J. Zhou et al.   MOLECULAR CANCER THERAPEUTICS

Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines

(2008) Azhar R. Hussain et al.   MOLECULAR CANCER THERAPEUTICS

Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression

(2007) Vladimir N. Ivanov et al.   EXPERIMENTAL CELL RESEARCH